Search

Plinabulin

AMG-222

Aldoxorubicin

Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.

C326

The drug is composed of an IL-6–binding trimer and a IgG-binding domain. … C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment

Filanesib

Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.

Olaratumab

Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity … It is composed of two heavy chain molecule fragments and 2 light chain fragments.

TC-2216

TC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders. TC-2216 showed greater potency than and anti-depressant effects comparable to selective serotonin reupt...

Linsitinib

An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.

Lumateperone

Schizophrenia is a complex mental illness and impacts approximately 1% of the population. … [A189093] Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.[A189093,L10908]

Caplacizumab

Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.